A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer
Phase: Phase III clinical trials
Principal Investigator: Dott.ssa Brambilla Marta
Main Facility: Oncologia Medica 1
Drug: V940 (mRNA-4157)
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
Phase 3 clinical trial for patients with early-stage non-small cell lung cancer (Stage I, high risk) that has already been completely removed by surgery. The purpose of the study is to evaluate the effectiveness of a preventive therapy to stop the tumor from coming back. Participants are divided into three groups to receive different treatments. The first group receives a combination of two investigational drugs (the mRNA vaccine Intismeran, also known as V940, via an injection into the muscle every 3 weeks, and MK-3475A via an injection under the skin every 6 weeks, both for a total of 9 doses). The second group receives only the drug Intismeran (V940) combined with a placebo. The third group receives only a placebo via an injection into the muscle every 3 weeks for a total of 9 doses. In the first group, the treatments are known, while in the other cases, neither the doctor nor the patient will know which substance has been assigned, ensuring the maximum objectivity of the results.
Last update: 06/10/2026